Last reviewed · How we verify
NCT05471063
Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis
NA trial testing Amphotericin B Colloidal Dispersion in Cryptococcal Meningitis in 30 participants. Status unknown.
28 February 2023
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 22 August 2022 |
| Primary completion | 28 February 2023 |
| Estimated completion | 30 April 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Amphotericin B Colloidal Dispersion — full drug profile →
- flucytosine (FLUCYTOSINE) — full drug profile →
- fluconazole (fluconazole) — full drug profile →
Conditions studied
- Cryptococcal Meningitis — all drugs for Cryptococcal Meningitis →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 70, any sex, with Cryptococcal Meningitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy and safety of ABCD in the treatment of cryptococcal meningitis in non-HIV patients at week 4, the end of induction therapy, week 10 and the end of consolidation therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05471063
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cryptococcal Meningitis
Currently open trials in the same condition.
- NCT06666322 — Platform Trial For Cryptococcal Meningitis · Phase 2, PHASE3 · recruiting
- NCT00867269 — Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia · recruiting
- NCT00001352 — Fungal Infection Susceptibility · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05471063 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 22 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05471063.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing